Healx Doses First Patient in HLX-4310 Phase 1/2 Trial
CAMBRIDGE, UK, July 22, 2026 Healx, an AI-powered clinical-stage biotechnology company, has announced that the first patient has been...
rare cancer
Advertisement
US WorldMeds Secures Full FDA Approval for TECELRA
LOUISVILLE, Kentucky, June 22, 2026 US WorldMeds has announced that the U.S. Food and Drug Administration (FDA) has granted...
Servier’s Emi-Le Shows Promise in Rare ACC Cancer Trial
BOSTON, June 1, 2026 Servier has announced encouraging new clinical findings for Emiltatug Ledadotin (Emi-Le), an investigational B7-H4-targeted antibody-drug...
Cogent’s Bezuclastinib Gains FDA Priority Review for GIST
WALTHAM, Mass. and BOULDER, Colo., May 28, 2026 Cogent Biosciences has announced a major regulatory milestone with the U.S....
AbbVie Wins FDA Approval for DECNUPAZ in Rare Blood Cancer
NORTH CHICAGO, Ill., May 27, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ™...
Advertisements
Partner Therapeutics Strengthens Oncology Portfolio With BIZENGRI
LEXINGTON, Mass., May 11, 2026 Partner Therapeutics, Inc. (PTx) announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Bizengri for Rare Cholangiocarcinoma
SILVER SPRING, Maryland, May 8, 2026 The U.S. Food and Drug Administration (FDA) has approved Bizengri (zenocutuzumab-zbco) for the...
Oncolytics Advances Pelareorep Toward Anal Cancer Approval
San Diego, California, USA, April 6, 2026 FDA Engagement Signals Registrational Pathway Progress In a key development for oncolytic...
Day One Biopharma Acquires Mersana to Advance ADC Pipeline
BRISBANE, CA – November 13, 2025 — Day One Biopharmaceuticals announced a definitive agreement to acquire Mersana Therapeutics in...
Crinetics Unveils Neuroendocrine Tumour Data at NANETS 2025
SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North...
Advertisement
